Cellular and molecular mechanisms of metformin: an overview
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first-line oral therapy for T2D (Type 2 diabetes). The main effect of this drug from the biguanide family is to acutely decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The demonstration that respiratory chain complex I, but not AMPK, is the primary target of metformin was recently strengthened by showing that the metabolic effect of the drug is preserved in liver-specific AMPK-deficient mice. Beyond its effect on glucose metabolism, metformin has been reported to restore ovarian function in PCOS (polycystic ovary syndrome), reduce fatty liver, and to lower microvascular and macrovascular complications associated with T2D. Its use has also recently been suggested as an adjuvant treatment for cancer or gestational diabetes and for the prevention in pre-diabetic populations. These emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In PCOS, metformin reduces insulin resistance and inhibits ovarian androgen production via effects on steroidogenic acute regulatory protein and 17alphahydroxylase (Diamanti-Kandarakis et al. , 2010; Viollet et al. , 2012).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Viollet et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“a drug that is currently being used to treat type II diabetic patients, metformin [74], can activate AMPK”
From Senescence of T Lymphocytes: Implications for Enhancing Human Immunity (2016) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Given the evidence that metformin acts through the mitochondrial electron transport chain (ETC) by inhibiting complex I(46, 210–212) (Figure 8)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
In the citing paper
“By far the most important mechanism is the reduction in hepatic glucose production that is considered mediated by the activation of the global energy sensor in cells, adenosine monophosphate-activated protein kinase (AMPK) (Figure 1).(46)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 4×
“Thus, AMPK activation by metformin induces the phosphorylation and inactivation of acetyl CoA carboxylase (ACC), an important rate-controlling enzyme for the synthesis of malonylCoA, which is both a critical precursor for the biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation [17].”
BackgroundInfluentialHyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Furthermore, the authors found a doseresponse relationship between duration of exposure to metformin and cancer incidence [106].”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 25×
“Metformin most likely does not directly activate either LKB1 or AMPK as the drug does not influence the phosphorylation of AMPK by LKB1 in cell-free assay [21].”
BackgroundInfluential
Cited by
Items 601–700 of 1,001
Recent insights into the effects of metabolism on breast cancer cell dormancy
Bartlome, S., & Berry, C. C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01869-5 · Cited by 43
PET Tracers To Study Clinically Relevant Hepatic Transporters
Testa, A., Zanda, M., Elmore, C. S., & Sharma, P. K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00059 · Cited by 38
Zhai, L., Gu, J., Yang, D., Wang, W., & Ye, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/231825 · Cited by 34
Hohnholt, M. C., Blumrich, E., Waagepetersen, H. S., & Dringen, R. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24050 · Cited by 34
BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment
Andrieu, G. P., Shafran, J. S., Deeney, J. T., Bharadwaj, K. R., Rangarajan, A., & Denis, G. V. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0917-380rr · Cited by 35
Abdalla, M. A., Shah, N., Deshmukh, H., Sahebkar, A., Östlundh, L., Al-Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221127142 · Cited by 33
Insulin resistance in cancer risk and prognosis
Jacobo-Tovar, E., Medel-Sánchez, A., Durán-Castillo, C., & Guardado‐Mendoza, R. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.006 · Cited by 36
Negative regulation of Bmi-1 by AMPK and implication in cancer progression
Huang, D., He, X., Zou, J., Guo, P., Jiang, S., Lv, N., Alekseyev, Y. O., Luo, L., & Luo, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.6748 · Cited by 33
Hyperglycemia-Induced Endothelial Dysfunction
Gerő, D. (2018) · InTech eBooks · doi:10.5772/intechopen.71433 · Cited by 39
Mitochondrial targets of metformin—Are they physiologically relevant?
Pecinová, A., Brázdová, A., Drahota, Z., Houštěk, J., & Mráček, T. (2019) · BioFactors · doi:10.1002/biof.1548 · Cited by 33
Obafemi, T. O., Olasehinde, O. R., Olaoye, O. A., Jaiyesimi, K. F., Adewumi, F. D., Adewale, O. B., & Afolabi, B. A. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00541-0 · Cited by 35
Metformin May Contribute to Inter-individual Variability for Glycemic Responses to Exercise
Malin, S. K., & Stewart, N. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00519 · Cited by 34
Metformin - its anti-cancer effects in hematologic malignancies
Podhorecka, M. (2021) · Oncology Reviews · doi:10.4081/oncol.2021.514 · Cited by 33
Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes
Lu, S., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · Epidemiology · doi:10.1097/ede.0000000000001486 · Cited by 34
The role of metformin as a treatment for neuropsychiatric illness
Dodd, S., Sominsky, L., Siskind, D. J., Bortolasci, C. C., Carvalho, A. F., Maes, M. H. J., Walker, A. J., Walder, K. R., Yung, A. R., Williams, L. J., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.002 · Cited by 34
Ebrahimi, H., Nezhad, S. K., Farmoudeh, A., Babaei, A., Ebrahimnejad, P., Akbari, E., & Siahposht-Khachaki, A. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.10.018 · Cited by 35
Yang, R., Yu, H., Wu, J., Chen, H., Wang, M., Wang, S., Qin, X., Wu, T., Wu, Y., & Hu, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1082720 · Cited by 33
Abdulrahman, R. M., Boon, M. R., Sips, H. C. M., Guigas, B., Rensen, P. C. N., Smit, J. W. A., & Hovens, G. C. J. (2014) · Thyroid · doi:10.1089/thy.2013.0041 · Cited by 34
Self-citationCongenital Lipodystrophies and Dyslipidemias
Prieur, X., May, C. L., Magré, J., & Cariou, B. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0437-x · Cited by 36
Mahrooz, A., Parsanasab, H., Hashemi‐Soteh, M. B., Kashi, Z., Bahar, A., Alizadeh, A., & Mozayeni, M. (2014) · Clinical and Experimental Medicine · doi:10.1007/s10238-014-0283-8 · Cited by 34
Metformin in women with PCOS, Pros
Pasquali, R. (2014) · Endocrine · doi:10.1007/s12020-014-0311-1 · Cited by 39
Pojoga, L. H., Yao, T. M., Opsasnick, L. A., Garza, A., Reslan, O. M., Adler, G. K., Williams, G. H., & Khalil, R. A. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.209189 · Cited by 33
Adaramoye, O. A., & Lawal, S. O. A. (2013) · Andrologia · doi:10.1111/and.12160 · Cited by 35
Metformin and Pancreatic Cancer: A Clue Requiring Investigation
Pollak, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0694 · Cited by 32
Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression
Erices, R., Cubillos, S., Aravena, R., Santoro, F., Marquez, M., Orellana, R., Ramírez, C., González, P., Fuenzalida, P., Bravo, M. L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15348 · Cited by 34
Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats
Qi, H., Nielsen, P. M., Schroeder, M., Bertelsen, L. B., Palm, F., & Laustsen, C. (2017) · Diabetologia · doi:10.1007/s00125-017-4445-6 · Cited by 35
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
Cariou, B., & Staels, B. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.954034 · Cited by 36
Carroll, C. M., & Macauley, S. L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00258 · Cited by 32
“Metformin, the antihyperglycemic drug and first-line treatment for T2D, reduces hepatic gluconeogenesis, plasma insulin, and insulin resistance (Viollet et al., 2012).”
BackgroundMetformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
Elia, E. M., Quintana, R., Carrere, C., Bazzano, M. V., Valzacchi, G. R., Paz, D. A., & Pustovrh, M. C. (2013) · Journal of Ovarian Research · doi:10.1186/1757-2215-6-62 · Cited by 35
Breier, M., Wahl, S., Prehn, C. P., Ferrari, U., Sacco, V., Weise, M., Grallert, H., Adamski, J., & Lechner, A. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.08.004 · Cited by 32
Spectroscopic and thermodynamic studies of the binding mechanism of metformin to pepsin
Pathak, M., Sharma, D., Sharma, N., & Sharma, M. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.04.032 · Cited by 32
Wang, S., Xia, Y., Ma, T., Weir, M. D., Ren, K., Reynolds, M. A., Shu, Y., Cheng, L., Schneider, A., & Xu, H. H. K. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-00600-3 · Cited by 35
Tan, M. K. X., Heng, T. Y. J., & Mak, A. (2019) · Cells · doi:10.3390/cells8040323 · Cited by 32
Lei, R., Zhang, S., Wang, Y., Dai, S., Sun, J., & Zhu, C. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.32157 · Cited by 34
Javadipour, M., Rezaei, M., Keshtzar, E., & Khodayar, M. J. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22368 · Cited by 33
Diabetes and its Potential Impact on Head and Neck Oncogenesis
Wang, X., Wang, H., Zhang, T., Cai, L., Dai, E., & He, J. (2019) · Journal of Cancer · doi:10.7150/jca.35607 · Cited by 33
Metformin as a Potential Treatment Option for Endometriosis
Kimber-Trojnar, Ż., Dłuski, D. F., Wierzchowska-Opoka, M., Ruszała, M., & Leszczyńska‐Gorzelak, B. (2022) · Cancers · doi:10.3390/cancers14030577 · Cited by 35
Chhunchha, B., Kubo, E., & Singh, D. P. (2022) · Cells · doi:10.3390/cells11193021 · Cited by 33
Kharmats, A. Y., Popp, C. J., Hu, L., Berube, L. T., Curran, M., Wang, C., Pompeii, M. L., Li, H., Bergman, M., St‐Jules, D. E., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.026 · Cited by 32
Papadakos, S. P., Ferraro, D., Carbone, G., Frampton, A. E., Vennarecci, G., Kykalos, S., Schizas, D., Theocharis, S. E., & Machairas, N. (2023) · Cancers · doi:10.3390/cancers15123161 · Cited by 32
Inhibition of tumor energy pathways for targeted esophagus cancer therapy
Shafaee, A., Dastyar, D. Z., Islamian, J. P., & Hatamian, M. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.005 · Cited by 34
Glossmann, H. H., & Reider, N. (2013) · Dermato-Endocrinology · doi:10.4161/derm.23874 · Cited by 35
Jang, E. K., Kim, W. G., Kwon, H., Choi, Y. M., Jeon, M. J., Kim, T. Y., Shong, Y. K., Kim, W. B., & Kim, E. Y. (2015) · European Thyroid Journal · doi:10.1159/000437365 · Cited by 32
Antu, K. A., Riya, M. P., Mishra, A., Anilkumar, K. S., Chandrakanth, C. K., Tamrakar, A. K., Srivastava, A. K., & Raghu, K. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105829 · Cited by 38
Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Villalba, M., López-Royuela, N., Krzywińska, E., Rathore, M. G., Hipskind, R. A., Haouas, H., & Allende-Vega, N. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113136660374 · Cited by 34
Drugs and mitochondrial diseases: 40 queries and answers
Mancuso, M., Orsucci, D., Filosto, M., Simoncini, C., & Siciliano, G. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657177 · Cited by 36
Kuo, Y., Lin, C., Shih, C., & Yang, C.-S. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/4867092 · Cited by 34
Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion
Rodríguez-Lara, S. Q., Cardona-Muñóz, E. G., Ramírez-Lizardo, E. J., Totsuka-Sutto, S. E., Castillo‐Romero, A., García-Cobián, T. A., & García‐Benavides, L. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7190943 · Cited by 33
Targosz‐Korecka, M., Malek-Zietek, K. E., Klóska, D., Rajfur, Z., Stępień, E. Ł., Grochot‐Przeczek, A., & Szymoński, M. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129533 · Cited by 34
Matsiukevich, D., Piraino, G., Lahni, P. M., Hake, P. W., Wolfe, V., O’Connor, M. P., James, J., & Zingarelli, B. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.05.027 · Cited by 34
Alshishani, A., Salhimi, S. M., & Saad, B. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.12.013 · Cited by 32
Shehata, T. M., & Ibrahim, M. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1680992 · Cited by 31
Fernandes, J. M., Jandrey, E. H. F., Koyama, F. C., Leite, K. R. M., Camargo, A. A., Costa, É. T., Perez, R. O., & Asprino, P. F. (2020) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001626 · Cited by 37
Adikesavalu, H., Gopalaswamy, R., Kumar, A., Ranganathan, U. D., & Shanmugam, S. (2021) · Medicina · doi:10.3390/medicina57060522 · Cited by 34
Visioli, F., Ingram, A., Beckman, J. S., Magnusson, K. R., & Hagen, T. M. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.12.008 · Cited by 31
Hu, N., Zhang, Q., Wang, H., Yang, X., Jiang, Y., Chen, R., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794103 · Cited by 36
Gagnon, J., Sheppard, E., & Anini, Y. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12021 · Cited by 31
Metformin Induces Cell Cycle Arrest and Apoptosis in Drug-Resistant Leukemia Cells
Rodríguez-Lirio, A., Pérez‐Yarza, G., Fernández-Suárez, M. R., Alonso-Tejerina, E., Boyano, M. D., & Asumendi, A. (2015) · Leukemia Research and Treatment · doi:10.1155/2015/516460 · Cited by 31
Hanprasertpong, J., Jiamset, I., Geater, A. F., Peerawong, T., Hemman, W., & Kornsilp, S. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000855 · Cited by 31
PPP1R3C mediates metformin-inhibited hepatic gluconeogenesis
Ji, X., Wang, S., Tang, H., Zhang, Y., Zhou, F., Zhang, L., Zhu, Q., Zhu, K., Liu, Q., Liu, Y., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.002 · Cited by 34
Ravera, S., Cossu, V., Tappino, B., Nicchia, E., Dufour, C., Cavani, S., Sciutto, A., Bolognesi, C., Columbaro, M., Degan, P., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26085 · Cited by 30
Regulation of myoblast differentiation by metabolic perturbations induced by metformin
Pavlidou, T., Rosina, M., Fuoco, C., Gerini, G., Gargioli, C., Castagnoli, L., & Cesareni, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182475 · Cited by 33
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer
Nunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207768 · Cited by 34
Metal Complex Formation and Anticancer Activity of Cu(I) and Cu(II) Complexes with Metformin
Abdelrahman, S., Alghrably, M., Campagna, M., Hauser, C. A. E., Jaremko, M., & Lachowicz, J. I. (2021) · Molecules · doi:10.3390/molecules26164730 · Cited by 38
Guarnaccia, L., Navone, S. E., Masseroli, M. M., Balsamo, M., Caroli, M., Valtorta, S., Moresco, R. M., Campanella, R., Garzia, E., Riboni, L., et al. (2021) · Cancers · doi:10.3390/cancers14010112 · Cited by 31
Singh, R., Sarangi, S. C., Singh, S., & Tripathi, M. (2022) · Seizure · doi:10.1016/j.seizure.2022.09.003 · Cited by 31
Ramachandran, R., & Saraswathy, M. (2014) · Toxicology Research · doi:10.1039/c4tx00032c · Cited by 35
Ward, N. P., Poff, A. M., Koutnik, A. P., & D’Agostino, D. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180061 · Cited by 32
New Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus
Catalina, M. O., Redondo, P. C., Granados, M. P., Cantonero, C., Sánchez-Collado, J., Albarrán, L., & López, J. J. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171205162248 · Cited by 32
Wandee, J., Prawan, A., Senggunprai, L., Kongpetch, S., & Kukongviriyapan, V. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.12.007 · Cited by 30
A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity
Kim, K., Yang, W., Jung, Y., & Cha, J. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.10.149 · Cited by 31
Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
Ying, M., Maruschak, N., Mansur, R., Carvalho, A., Cha, D., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130205514 · Cited by 29
Śmieszek, A., Basińska, K., Chrząstek, K., & Marycz, K. (2015) · Journal of Diabetes Research · doi:10.1155/2015/814896 · Cited by 33
Iversen, A. B. B., Horsman, M. R., Jakobsen, S., Jensen, J., Garm, C., Jessen, N., Breining, P., Frøkiær, J., & Busk, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10010-z · Cited by 29
PCB126 Inhibits the Activation of AMPK-CREB Signal Transduction Required for Energy Sensing in Liver
Gadupudi, G. S., Elser, B. A., Sandgruber, F. A., Li, X., Gibson-Corley, K. N., & Robertson, L. W. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy041 · Cited by 32
Odeyemi, S. W., & Dewar, J. B. (2019) · Processes · doi:10.3390/pr8010033 · Cited by 33
How metformin affects various malignancies by means of microRNAs: a brief review
Alimoradi, N., Firouzabadi, N., & Fatehi, R. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01921-z · Cited by 29
Palei, N. N., & Surendran, V. (2021) · Current Drug Delivery · doi:10.2174/1567201818666211005090656 · Cited by 29
El-Kafrawy, D. S., El-Shoubashy, O. H., Issa, A. E., & Beltagy, Y. A. (2021) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2021.100560 · Cited by 29
Advances in metformin‑based metabolic therapy for non‑small cell lung cancer (Review)
Chen, N., Zhou, Y.-S., Wang, L.-C., & Huang, J. (2022) · Oncology Reports · doi:10.3892/or.2022.8266 · Cited by 29
Living long and ageing well: is epigenomics the missing link between nature and nurture?
The ACUME2 Project, Rea, I. M., Dellett, M., & Mills, K. (2015) · Biogerontology · doi:10.1007/s10522-015-9589-5 · Cited by 32
Insulin Sensitizers in Polycystic Ovary Syndrome
Pasquali, R., & Gambineri, A. (2012) · Frontiers of hormone research · doi:10.1159/000341837 · Cited by 30
Mughal, A., Kumar, D., & Vikram, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.10.057 · Cited by 32
Zaharenko, L., Kalniņa, I., Geldnere, K., Konrāde, I., Grīnberga, S., Židzik, J., Javorský, M., Lejnieks, A., Ņikitina-Zaķe, L., Frīdmanis, D., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0347 · Cited by 30
The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug
Sacco, F., Calderone, A., Castagnoli, L., & Cesareni, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.385 · Cited by 33
Cummings, B. M., Needoba, J. A., & Peterson, T. D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207041 · Cited by 30
Kajbaf, F., Fendri, S., Basille‐Fantinato, A., Diouf, M., Rose, D., Jounieaux, V., & Lalau, J. ‐. (2014) · Diabetic Medicine · doi:10.1111/dme.12362 · Cited by 29
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
Wang, D., & He, B. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s362424 · Cited by 28
“As a result, glucose, lipid and protein synthesis as well as cell growth are inhibited, while fatty acid oxidation and glucose uptake are stimulated.(91) AMPK can mediate phosphorylation of target substrates,(92) attenuating NAFLD”
BackgroundMetformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention
Pulito, C., Sanli, T., Rana, P., Muti, P. C., Blandino, G., & Strano, S. (2013) · Metabolites · doi:10.3390/metabo3041051 · Cited by 33
Kikuchi, S., Piraino, G., O’Connor, M. P., Wolfe, V., Ridings, K., Lahni, P. M., & Zingarelli, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00210 · Cited by 28
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 30
Salter, D. M., Wei, W., Nahar, P. P., Marques, E., & Slitt, A. L. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab043 · Cited by 29
Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2
Sun, X., Dong, M., Gao, Y., Wang, Y., Du, L., Liu, Y., Wang, Q., Ji, K., He, N., Wang, J., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114981 · Cited by 29
Sciacca, L., Bianchi, C., Burlina, S., Formoso, G., Manicardi, E., Sculli, M. A., & Resi, V. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02137-5 · Cited by 33
Do metformin a real anticarcinogen? A critical reappraisal of experimental data.
Anisimov, V. N. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.06.02 · Cited by 32
New insight for metformin against bladder cancer
El‐Arabey, A. A. (2017) · Genes and Environment · doi:10.1186/s41021-017-0074-z · Cited by 28
Lan, P., Romero, F. A., Wódka, D., Kassick, A. J., Dang, Q., Gibson, T., Cashion, D. K., Zhou, G., Chen, Y., Zhang, X., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01344 · Cited by 28
Thyroid function in hidradenitis suppurativa: a population-based cross-sectional study from Denmark
Miller, I. M., Vinding, G. R., Sørensen, H. A., Rytgaard, H. C. W., Mogensen, U. B., Ellervik, C., & Jemec, G. B. E. (2018) · Clinical and Experimental Dermatology · doi:10.1111/ced.13606 · Cited by 28
Han, X., Wang, B., Sun, Y., Huang, J., Wang, X., Ma, W., Zhu, Y., Xu, R., Jin, H. L., & Liu, N. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01266 · Cited by 32
Pujimulyani, D., Yulianto, W. A., Setyowati, A., Arumwardana, S., Kusuma, H. S. W., Sholihah, I. A., Rizal, R., Widowati, W., & Maruf, A. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267912 · Cited by 28
Metadata
- Authors
- Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F.
- Affiliations
- INSERM, U1016, Institut Cochin, Paris, France
- Leiden University Medical Center (NL)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Leclerc, Jocelyne
- Foretz, Marc
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2011-11-11
- Volume
- 122
- Issue
- 6
- Pages
- 253-270
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- PMC
- PMC3398862
- OpenAlex
- W2154024784
- Cited by
- 1,720
- References
- 167
- Citations by year
- 2026: 63 · 2025: 85 · 2024: 96 · 2023: 103 · 2022: 106 · 2021: 143 · 2020: 155 · 2019: 135 · 2018: 141 · 2017: 156 · 2016: 137 · 2015: 144 · 2014: 117 · 2013: 104 · 2012: 34
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, type 2 diabetes, biguanides, AMPK, mitochondrial complex I inhibition, hepatic gluconeogenesis, hepatic glucose production, polycystic ovary syndrome, hepatic steatosis, diabetes complications, adjuvant cancer therapy, gestational diabetes mellitus, prediabetes, pharmacogenetics, personalized medicine
- MeSH terms
- Animals, Cardiovascular System, Diabetic Nephropathies, Female, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Polycystic Ovary Syndrome, Circadian Clocks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.